Kaddis said insurers are locked in a cat-and-mouse game with drugmakers as the insurance sector invests in biosimilars and ...

Forget the needle.

Science-Backed PhenQ Supplement Offers a Natural, Multi-Action Alternative to GLP-1 Drugs Like Ozempic-Empowering 2025 Weight ...

1️⃣ ‘Summer of hell’: What’s typically a key money-making time for airlines could fall short this year. Fears about flying, ...

Noom will start offering smaller doses of compounded Wegovy (NVO), the blockbuster weight-loss drug, as the digital health ...

"The changes are made in light of the recent market challenges Novo Nordisk has been facing, and the development of the ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Alzheimer's disease costs the global economy $1.3trillion a year. That is the estimate from the Alzheimer's Society.

NVO stock declines 3% as the company announces that Lars Fruergaard Jorgensen will be stepping down as the CEO.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

Japan-based Fujirebio's test, which helps doctors diagnose Alzheimer's disease, is intended for patients with signs of ...

Novo Nordisk CEO Lars Fruergaard Jørgensen will step down after eight years at the helm, as the Danish pharmaceutical giant ...